Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 26:15:34.
doi: 10.1186/s12906-015-0556-0.

Anti-emetic mechanisms of Zingiber officinale against cisplatin induced emesis in the pigeon; behavioral and neurochemical correlates

Ihsan Ullah  1   2 , Fazal Subhan  3 , Muhammad Ayaz  4 , Rehmat Shah  5   6 , Gowhar Ali  7 , Ikram Ul Haq  8 , Sami Ullah  9
Affiliations

Anti-emetic mechanisms of Zingiber officinale against cisplatin induced emesis in the pigeon; behavioral and neurochemical correlates

Ihsan Ullah et al. BMC Complement Altern Med. .

Abstract

Background: Zingiber officinale (ZO, family Zingiberaceae) has been reported for its antiemetic activity against cancer chemotherapy induced emesis in animal models and in clinics. Current study was designed to investigate ZO for potential usefulness against cisplatin induced vomiting in pigeon and its effects on central and peripheral neurotransmitters involved in the act of vomiting.

Methods: Zingiber officinale acetone fraction (ZO-ActFr) was investigated for attenuation of emesis induced by cisplatin in healthy pigeons. Neurotransmitters DA, 5HT and their metabolites DOPAC, HVA and 5HIAA were analyzed using High Performance Liquid Chromatography system coupled with electrochemical detector in area postrema, brain stem and intestine. Antiemetic effect of ZO-ActFr was correlated with central and intestinal neurotransmitters levels in pigeon.

Results: Cisplatin (7 mg/kg i.v.) induced emesis without lethality upto the observation period. ZO-ActFr (25, 50 & 100 mg/kg) attenuated cisplatin induced emesis ~ 44.18%, 58.13% (P < 0.05) and 27.9%, respectively; the reference drug, metoclopramide (MCP; 30 mg/kg), produced ~ 48.83% reduction (P < 0.05). ZO-ActFr reduced (P < 0.05 - 0.001) 5-hydroxytryptamine (5HT) concentration in the area postrema, brain stem and intestine at 3(rd) hour of cisplatin administration, while at the 18(th) hour ZO treatments attenuated the dopamine upsurge (P < 0.001) caused by cisplatin in the area postrema and 5HT concentration (P < 0.01 - 0.001) in the brain stem and intestine. ZO treatments alone did not altered the basal neurotransmitters and their metabolites in the brain areas and intestine.

Conclusion: The behavioral study verify the antiemetic profile of ZO against cisplatin induced emesis in the pigeon, where central and peripheral neural evidences advocate the involvement of serotonergic mechanism at initial time point (3(rd) hr), while the later time point (18(th) hr) is associated with serotonergic and dopaminergic component in the mediation of its antiemetic effect.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Extraction scheme for Zingiber officinale acetone fraction.
Figure 2
Figure 2
The effect of Zingiber officinale acetone fraction (ZO-ActFr; 25, 50 & 100 mg/kg) and standard metoclopramide (MCP; 30 mg/kg) on cisplatin induced Retching plus Vomiting (R + V) during a 24 hr observation period. Each bar represents the mean ± s.e.m of R + V episodes occurring during 4 hr periods (n = 6–8).
See this image and copyright information in PMC

References

    1. Hesketh P, Grunberg SMG RJ, Warr DG, Roila F, De Wit R, Chawla SP, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112–9. doi: 10.1200/JCO.2003.01.095. - DOI - PubMed
    1. Coronas R, Pitarch L, Mallol J. Blockade of reserpine emesis in pigeons by metoclopramide. Eur J Pharmacol. 1975;32(2):380–2. doi: 10.1016/0014-2999(75)90309-X. - DOI - PubMed
    1. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 2012;88(3):497–9. doi: 10.1111/j.1476-5381.1986.tb10228.x. - DOI - PMC - PubMed
    1. Higgins G, Kilpatrick G, Bunce K, Jones B, Tyers M. 5HT3 receptor antagonists injected into the area postrema inhibit cisplatin induced emesis in the ferret. Br J Pharmacol. 2012;97(1):247–55. doi: 10.1111/j.1476-5381.1989.tb11948.x. - DOI - PMC - PubMed
    1. Perciedu Sert N, Rudd J, Apfel C, Andrews PLR. Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists. Cancer Chemother Pharmacol. 2011;67(3):667–86. doi: 10.1007/s00280-010-1339-4. - DOI - PMC - PubMed

Publication types